These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

730 related articles for article (PubMed ID: 29625593)

  • 1. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer.
    Shi S; Li B; Zhou P; Chen L; Li H; Wang Y; Deng X; Dang Q; Wu J; Zha B; Li P; Zheng Y; Yang D
    Cancer Med; 2024 Jul; 13(14):e7359. PubMed ID: 39032129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Antitumor Activity of Pembrolizumab in Patients With Programmed Death-Ligand 1-Positive Nasopharyngeal Carcinoma: Results of the KEYNOTE-028 Study.
    Hsu C; Lee SH; Ejadi S; Even C; Cohen RB; Le Tourneau C; Mehnert JM; Algazi A; van Brummelen EMJ; Saraf S; Thanigaimani P; Cheng JD; Hansen AR
    J Clin Oncol; 2017 Dec; 35(36):4050-4056. PubMed ID: 28837405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction chemotherapy followed by concurrent chemoradiation and nimotuzumab for locoregionally advanced nasopharyngeal carcinoma: preliminary results from a phase II clinical trial.
    Huang JF; Zhang FZ; Zou QZ; Zhou LY; Yang B; Chu JJ; Yu JH; Zhang HW; Yuan XP; Tai GM; Liu FJ; Ma CC
    Oncotarget; 2017 Jan; 8(2):2457-2465. PubMed ID: 27974693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I/II trial evaluating concurrent carbon-ion radiotherapy plus chemotherapy for salvage treatment of locally recurrent nasopharyngeal carcinoma.
    Kong L; Gao J; Hu J; Hu W; Guan X; Lu R; Lu JJ
    Chin J Cancer; 2016 Dec; 35(1):101. PubMed ID: 28007028
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative safety and efficacy of anti-PD-1 monotherapy, chemotherapy alone, and their combination therapy in advanced nasopharyngeal carcinoma: findings from recent advances in landmark trials.
    Lv JW; Li JY; Luo LN; Wang ZX; Chen YP
    J Immunother Cancer; 2019 Jun; 7(1):159. PubMed ID: 31238988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiotherapy Combined with PD-1 Inhibition Increases NK Cell Cytotoxicity towards Nasopharyngeal Carcinoma Cells.
    Makowska A; Lelabi N; Nothbaum C; Shen L; Busson P; Tran TTB; Eble M; Kontny U
    Cells; 2021 Sep; 10(9):. PubMed ID: 34572108
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort.
    Yao Y; Ouyang Q; Wang S; Li K; Luo Q; Qiu L; Liu F; Tan L; Li Q; Ren B; Long P; Ye J; Zhong X
    Oral Oncol; 2024 Jul; 154():106867. PubMed ID: 38797001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful replacement for recurrent nasopharyngeal carcinoma with cholecystitis induced by PD-1 antibody: a case report.
    Liu Z; Du X; Deng M; Chen Y; Wu S
    Immunotherapy; 2024; 16(14-15):949-953. PubMed ID: 39229795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case report: Immunotherapy-based combination therapy achieving complete remission and prolonged survival in nasopharyngeal carcinoma with extensive bone marrow metastasis.
    Wang X; Yuan Y; Zhang Y; Qiao G; Chen S; Huang W; Zhang J
    Front Immunol; 2024; 15():1410250. PubMed ID: 38979408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population.
    Chen WC; Chu PY; Lee YT; Lu WB; Liu CY; Chang PM; Yang MH
    Medicine (Baltimore); 2017 Dec; 96(52):e9519. PubMed ID: 29384959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature.
    Carausu M; Beddok A; Langer A; Girard N; Bidard FC; Massiani MA; Ricard D; Cabel L
    J Immunother Cancer; 2019 Nov; 7(1):317. PubMed ID: 31753021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current management of stage IV nasopharyngeal carcinoma without distant metastasis.
    Ng WT; Corry J; Langendijk JA; Lee AWM; Mäkitie A; Mendenhall WM; Rinaldo A; Rodrigo JP; Saba NF; Smee R; Strojan P; Suárez C; Vermorken JB; Ferlito A
    Cancer Treat Rev; 2020 Apr; 85():101995. PubMed ID: 32113080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report.
    Li D; He C; Xia Y; Du Y; Zhang J
    J Med Case Rep; 2018 Apr; 12(1):104. PubMed ID: 29681240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe immune mucositis and esophagitis in metastatic squamous carcinoma of the larynx associated with pembrolizumab.
    Acero Brand FZ; Suter N; Adam JP; Faulques B; Maietta A; Soulières D; Blais N
    J Immunother Cancer; 2018 Mar; 6(1):22. PubMed ID: 29548299
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy followed by adjuvant chemotherapy in locally advanced nasopharyngeal carcinoma.
    Setakornnukul J; Thephamongkhol K
    BMC Cancer; 2018 Mar; 18(1):329. PubMed ID: 29587665
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage Endoscopic Skull Base Surgery: Another Treatment Option After Immunotherapy for Recurrent Nasopharyngeal Carcinoma.
    Peng Z; Wang Y; Fang Y; Wang Y; Yuan X; Shuai M; Xie S; Fan R; Zhang H; Xie Z; Jiang W
    Front Immunol; 2022; 13():899932. PubMed ID: 35686123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Image-based diagnosis of residual or recurrent nasopharyngeal carcinoma may be a phantom tumor phenomenon.
    Lee CC; Lee JC; Huang WY; Juan CJ; Jen YM; Lin LF
    Medicine (Baltimore); 2021 Feb; 100(8):e24555. PubMed ID: 33663063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prolonged complete remission after induction chemotherapy followed by chemoradiation with tomotherapy in metastatic nasopharyngeal cancer.
    Agnese D; Belgioia L; Bacigalupo A; Marcenaro M; Vecchio S; Agostinelli S; Morbelli S; Corvò R
    Anticancer Res; 2014 Sep; 34(9):5075-8. PubMed ID: 25202093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term treatment outcome of recurrent nasopharyngeal carcinoma treated with salvage intensity modulated radiotherapy.
    Hua YJ; Han F; Lu LX; Mai HQ; Guo X; Hong MH; Lu TX; Zhao C
    Eur J Cancer; 2012 Dec; 48(18):3422-8. PubMed ID: 22835782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.